Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hosam Hakim"'
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 14, Iss 1 (2022)
In the modern era, classification of neoplasms not only depends on immunomorphological features but also on specific disease defining genetic events. Translocations/rearrangements of MYC/8q24 locus in combination with BCL-2 or BCL6 translocations (do
Externí odkaz:
https://doaj.org/article/79e9ec932c8341bcbb898a16b38559f0
Autor:
Imtiaz Ismail, Khalid Al-Khafaji, Monica Mutyala, Saurabh Aggarwal, William Cotter, Hosam Hakim, Sandeep Khosla, Rohit Arora
Publikováno v:
Journal of Community Hospital Internal Medicine Perspectives, Vol 5, Iss 0, Pp 1-2 (2015)
Lipomas of the heart are encapsulated tumors that are composed primarily of mature fat cells. Cardiac lipomas can originate either from subendocardium (approximately 50%), subpericardium (25%), or from the myocardium (25%) and may be located more fre
Externí odkaz:
https://doaj.org/article/d741cce43f20485c96873186ce027f87
Autor:
Laura Kohler, Zachary Pounders, Aditi Singh, Rida Jamal, Zeyad Sako, Adrian Tsui, Joseph Attallah, Daniel Lebovic, Zyad Kafri, Carrie Lynn Dul, Hosam Hakim, Jeffrey Lei
Publikováno v:
Blood. 140:11074-11075
Autor:
Aditi Singh, Hemang Patel, Ahmed Abdalla, Talal Bazzi, Mohamed Issa, Hussein Gharib, Laura Kohler, Natali Salaytah, Nilamben Mangukia, Hosam Hakim, Carrie Lynn Dul, Zyad Kafri, Susan Szpunar, Daniel Lebovic, Louis Saravolatz
Publikováno v:
Blood. 140:5502-5503
Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis
Autor:
Nawfal Al-Khafaji, Yenal Harper, Khalid Al-Khafaji, Rohit Arora, Monica Mutyala, Imtiaz Ismail, Hosam Hakim
Publikováno v:
American Journal of Therapeutics. 24:e730-e736
Protease-activated receptor (PAR)-1 inhibitors have recently become popular in the use of atherosclerosis among clinicians. Atherosclerosis can cause cardiovascular and cerebrovascular events leading to one of the major causes of mortality worldwide.
Publikováno v:
Journal of Clinical Oncology. 37:e20646-e20646
e20646 Background: There have been numerous advances in the management of metastatic lung cancer, including targeted therapy against certain mutations in cancer cells and later developing immune therapy with check point inhibitors.From the pre-immune
Publikováno v:
Journal of Clinical Oncology. 35:e19533-e19533
e19533 Background: Plasma cell leukemia (PCL) is an aggressive malignancy with poor prognosis. Retrospective studies have suggested improved outcomes with stem cell transplant and use of novel agents. Methods: We used the Surveillance, Epidemiology,
Autor:
Hosam Hakim, Arindam Bagchi, Roland T. Skeel, Qiang Nai, William Barnett, Veena Iyer, Danae Hamouda
Publikováno v:
Journal of Clinical Oncology. 35:8524-8524
8524 Background: The optimal treatment of patients with Stage IIIA NSCLC, a heterogeneous group comprised of T1-T4, N0-N2 disease, is controversial. Lack of clear data and guidelines allows several options for treatment, and hence there has been sign